Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that develops the work in real estate technology, and healthcare sectors.
Business Model:
Revenue: $2.6B
Employees: 501-1,000
Rankings
Industries / Tags:
Detailed Alexandria Venture Investments Information
Geographic Data
Address: 26 North Euclid Avenue
City: Pasadena
State: CA
Zip: 91101
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$5B
Social
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company&s;s strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that are developing transformative new modalities and platforms to meaningfully improve human health.
Contact Phone:
+16265780777
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 12/2017 | Obsidian Therapeutics | Series A | 0 |
| 3/2018 | Prevail Therapeutics | Series A | 75M |
| 9/2021 | Acrigen Biosciences | Seed Round | - |
| 10/2019 | Adaptive Phage Therapeutics | Venture Round | 7M |
| 1/2022 | Avalo | Convertible Note | 750k |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 6/2022 | Dren Bio | Series B | 0 |
| 7/2021 | Wugen | Series B | 0 |
| 4/2021 | SeQure DX | Series A | 0 |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 1/2021 | Myeloid Therapeutics | Series A | 50M |
| 1/2021 | Encodia | Series C | 75M |
| 10/2018 | Stoke Therapeutics | Series B | 90M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 4/2021 | Alloy Therapeutics | Series C | 75M |
| 7/2019 | X-Vax Technology | Series A | 0 |
| 1/2019 | Frequency Therapeutics | Series B | - |
| 9/2018 | Epic Sciences | Series E | 0 |
| 9/2022 | Novome | Series B | 0 |
| 4/2017 | Arsanis | Series D | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 1/2019 | Immusoft | Series B | 0 |
| 10/2019 | Molecular Assemblies | Series A | 0 |
| 10/2022 | Odyssey Therapeutics | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 9/2021 | LEXEO Therapeutics | Series B | 0 |
| 3/2022 | Umaro Foods | Seed Round | 0 |
| 3/2022 | Eclipse Bioinnovations | Series A | 14M |
| 10/2021 | Crop Enhancement | Convertible Note | - |
| 1/2020 | TwinStrand Biosciences | Series A | 16M |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
| 10/2021 | Immunai | Series B | 215M |
| 8/2021 | Humacyte | PIPE | 175M |
| 5/2021 | Inari | Series D | 0 |
| 12/2017 | Aura Biosciences | Series C | 0 |
| 4/2023 | Function Oncology | Series A | 28M |
| 6/2021 | TRex Bio | Series A | 59M |
| 5/2021 | Invaio Sciences | Series C | 88.9M |
| 3/2019 | Cardea Bio | Series A | 7.8M |
| 1/2020 | Novome Biotechnologies | Series A | 0 |
| 9/2021 | Kytopen | Series A | 0 |
| 9/2018 | BlueLight Therapeutics | Series C | 20M |
| 9/2022 | Tavros Therapeutics | Seed Round | 7.5M |
| 12/2018 | Kallyope | Series B | 21M |
| 9/2020 | Korro Bio | Series A | 0 |
| 5/2018 | Celsius Therapeutics | Series A | 65M |
| 11/2021 | Parthenon Therapeutics | Series A | 0 |
| 12/2019 | Aspen Neuroscience | Seed Round | 0 |
| 8/2021 | Immunitas Therapeutics | Series B | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 8/2018 | Inari | Series B | 40M |
| 6/2019 | Encoded Therapeutics | Series C | 104M |
| 6/2021 | Bright Peak Therapeutics | Series B | 107M |
| 2/2022 | Harpe Bio | Venture Round | 3M |
| 11/2022 | Haystack Oncology | Series A | 56M |
| 12/2020 | Faze Medicines | Series A | 81M |
| 7/2021 | Axonis Therapeutics, Inc. | Venture Round | 0 |
| 2/2022 | Harpe Bio | Convertible Note | 3.2M |
| 3/2019 | Gencove | Seed Round | 3M |
| 9/2021 | Jasper Therapeutics | Post-IPO Equity | 0 |
| 1/2021 | LEXEO Therapeutics | Series A | 0 |
| 3/2017 | Boragen | Series A | 10M |
| 7/2021 | Deep Genomics | Series C | 0 |
| 8/2021 | Thryv Therapeutics | Series A | 0 |
| 2/2023 | Paratus Sciences | Series A | 0 |
| 7/2017 | Rodeo Therapeutics | Series A | 5.9M |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 3/2017 | EGenesis | Series A | 0 |
| 6/2021 | ImmuneID | Series A | 0 |
| 3/2019 | Karuna Therapeutics | Series B | 0 |
| 6/2020 | Autobahn Therapeutics | Series B | 76M |
| 4/2023 | Orbital Therapeutics | Series A | 0 |
| 3/2020 | Kallyope | Series C | 112M |
| 7/2018 | Compass Therapeutics, Inc. | Series A | 0 |
| 12/2022 | SonoThera | Series A | 0 |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 11/2018 | Caraway Therapeutics | Series A | 23M |
| 10/2017 | Visterra | Series C | 0 |
| 6/2018 | StrideBio | Series A | 15.7M |
| 5/2018 | Insitro | Series A | 100M |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 9/2017 | LifeMine Therapeutics | Series A | 0 |
| 11/2021 | GeneCentric Therapeutics | Series B | 0 |
| 5/2023 | Ten63 Therapeutics | Series A | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 12/2019 | Jasper Therapeutics | Series A | 35M |
| 7/2017 | Evelo Biosciences | Series B | 50M |
| 10/2017 | Cydan | Venture Round | 34M |
| 7/2021 | IgGenix | Series A | 0 |
| 9/2020 | Sonoma Pharmaceuticals | Post-IPO Equity | 70M |
| 7/2019 | GNS Healthcare | Series D | 23M |
| 9/2018 | OncoResponse | Series B | 40M |
| 9/2018 | MouSensor | Seed Round | 3.3M |
| 6/2020 | Element Biosciences | Series B | 30M |
| 2/2019 | Applied Therapeutics | Series B | 0 |
| 3/2022 | Creyon Bio | Series A | 0 |
| 10/2019 | Verseau Therapeutics | Equity | 50M |
| 1/2019 | Dewpoint Therapeutics | Series A | 60M |
| 4/2021 | Ventus Therapeutics | Series B | 100M |
| 11/2019 | Genetron Health | Series D | 71M |
| 1/2021 | AltPep | Series A | 23.1M |
| 6/2023 | AltPep | Series B | 0 |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 11/2017 | Codiak Biosciences | Series C | 76.5M |
| 4/2021 | Molecular Assemblies | Series A | 0 |
| 4/2018 | QurAlis | Seed Round | - |
| 1/2017 | Halio | Series C | 65M |
| 9/2018 | ENB Therapeutics | Series A | 8.1M |
| 12/2020 | Remix Therapeutics | Series A | 65M |
| 5/2018 | Nohla Therapeutics | Series B | 45M |
| 5/2021 | Marvin | Seed Round | 0 |
| 1/2023 | Melonfrost | Seed Round | 7M |
| 7/2020 | Compass Therapeutics, Inc. | Venture Round | 0 |
| 2/2017 | Applied Therapeutics | Series A | 6.1M |
| 1/2019 | Greenlight Biosciences | Venture Round | 50M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 11/2019 | miRecule | Seed Round | 0 |
| 10/2021 | IpiNovyx Bio | Seed Round | 0 |
| 5/2021 | miRecule | Venture Round | 0 |
| 10/2021 | Soli Organic | Venture Round | 0 |
| 9/2020 | Sonoma BioTherapeutics | Series A | 0 |
| 9/2019 | Boundless Bio | Series A | 46.4M |
| 3/2022 | Affini-T Therapeutics | Venture Round | 0 |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 10/2021 | DNA Script | Series C | 0 |
| 9/2018 | Silverback Therapeutics | Series A | 37.5M |
| 11/2022 | Cajal Neuroscience | Series A | 96M |
| 11/2018 | Ribometrix | Series A | 30M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 1/2018 | Skyhawk Therapeutics | Seed Round | 8M |
| 5/2021 | TwinStrand Biosciences | Series B | 50M |
| 6/2018 | Cibus | Series C | 70M |
| 12/2021 | Ambys Medicines | Series A | 47M |
| 6/2021 | Senda Biosciences | Series B | 0 |
| 4/2019 | Insitro | Series A | 100M |
| 9/2021 | Disc Medicine | Post-IPO Equity | 0 |
| 9/2021 | Disc Medicine | Series B | 90M |
| 9/2021 | Asher Bio | Series B | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 3/2019 | Imara | Series B | 0 |
| 9/2021 | Lycia Therapeutics | Series B | 70M |
| 3/2019 | Prevail Therapeutics | Series B | 50M |
| 9/2022 | Capstan Therapeutics | Series A | 102M |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 10/2019 | Variant Bio | Series A | 24.7M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 8/2018 | Magnolia NeuroSciences | Series A | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 12/2020 | Vigil Neuroscience | Series A | 50M |
| 5/2023 | Myeloid Therapeutics | Series A | 0 |
| 7/2018 | ORIG3N | Series B | 0 |
| 5/2023 | Myeloid Therapeutics | Series B | 0 |
| 6/2021 | Neurona Therapeutics | Venture Round | 0 |
| 10/2017 | Ribometrix | Seed Round | 7.5M |
| 5/2021 | BioTheryX | Series E | 92M |
| 10/2020 | Dren Bio | Series A | 0 |
| 1/2021 | Blacksmith Medicines | Seed Round | - |
| 5/2021 | Soteria Biotherapeutics | Series A | 42M |
| 3/2021 | StrideBio | Series B | 0 |
| 5/2021 | Advanced Animal Diagnostics | Series E | 0 |
| 8/2022 | Senda Biosciences | Series C | 123M |
| 3/2020 | Redpin Therapeutics | Series A | 15.5M |
| 1/2023 | Ensoma | Series B | 0 |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 7/2017 | Compass Therapeutics, Inc. | Series A | - |
| 3/2018 | TCR2 | Series B | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 3/2022 | TRex Bio | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 12/2022 | Dantari | Series A | 0 |
| 2/2022 | Kallyope | Series D | 0 |
| 11/2021 | Acrivon Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 2/2018 | Quentis | Series A | 48M |
| 1/2022 | Korro Bio | Series B | 0 |
| 1/2021 | Senti Biosciences | Series B | 105M |
| 12/2021 | NextVivo | Venture Round | 7.9M |
| 1/2019 | Tiburio Therapeutics | Series A | 31M |
| 3/2020 | Affinia Therapeutics | Series A | 0 |
| 6/2023 | Bitterroot Bio | Series A | 0 |
| 2/2022 | Ventus Therapeutics | Series C | 0 |
| 12/2020 | RayzeBio | Series B | 105M |
| 9/2017 | Gritstone Bio | Series B | 93M |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 9/2018 | Benson Hill | Series C | 65M |
| 3/2022 | Celsius Therapeutics | Series B | 0 |
| 2/2022 | Terray Therapeutics | Series A | 0 |
| 12/2019 | ImCheck Therapeutics | Series B | 53.2M |
| 10/2021 | Neumora Therapeutics | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2018 | Skyhawk Therapeutics | Venture Round | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 3/2020 | Silverback Therapeutics | Series B | 0 |
| 4/2021 | Boundless Bio | Series B | 105M |
| 4/2020 | MOMA Therapeutics | Series A | 86M |
| 5/2023 | Boundless Bio | Series C | 0 |
| 11/2022 | Rezo | Series A | 0 |
| 1/2021 | Vera Therapeutics | Series C | 0 |
| 3/2021 | Insitro | Series C | 400M |
| 2/2019 | Maze Therapeutics | Series A | 191M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2018 | NextCure | Series B | 93M |
| 9/2018 | System1 Biosciences | Series A | 25M |
| 6/2019 | BlackThorn Therapeutics | Series B | 76M |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 2/2018 | Kallyope | Series B | 66M |
| 10/2021 | Deka Biosciences | Series A | 0 |
| 7/2020 | Vesigen Therapeutics | Series A | 28.5M |
| 7/2022 | Ozette Technologies | Series A | 0 |
| 7/2022 | Cartography Biosciences | Series A | 0 |
| 7/2022 | Xilis | Series A | 0 |
| 6/2022 | DEM BioPharma | Series A | 0 |
| 6/2022 | Dren Bio | Series B | 0 |
| 5/2022 | Pleno | Seed Round | 0 |
| 5/2022 | Remix Therapeutics | Series B | 0 |
| 5/2022 | MOMA Therapeutics | Series B | 0 |
| 5/2022 | Aspen Neuroscience | Series B | 0 |
| 4/2022 | Pheast Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
